<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00087217</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02610</org_study_id>
    <secondary_id>PCI-03-152</secondary_id>
    <secondary_id>U01CA099168</secondary_id>
    <secondary_id>U01CA062502</secondary_id>
    <secondary_id>CDR0000373824</secondary_id>
    <nct_id>NCT00087217</nct_id>
  </id_info>
  <brief_title>17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor</brief_title>
  <official_title>Phase I Study of 17- Allylamino-17 Demethoxygeldanamycin (17-AAG) in Combination With Paclitaxel in Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of
      17-N-allylamino-17-demethoxygeldanamycin when given together with paclitaxel in treating
      patients with metastatic or unresectable solid tumor. Drugs used in chemotherapy, such as
      17-N-allylamino-17-demethoxygeldanamycin and paclitaxel, work in different ways to stop tumor
      cells from dividing so they stop growing or die. Combining
      17-N-allylamino-17-demethoxygeldanamycin with paclitaxel may kill more tumor cells
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      I. Determine the maximum tolerated dose and recommended phase II dose of
      17-N-allylamino-17-demethoxygeldanamycin (17-AAG) when administered with paclitaxel in
      patients with metastatic or unresectable solid malignancy.

      II. Determine the dose-limiting and non-dose-limiting toxic effects of this regimen in these
      patients.

      III. Determine the pharmacokinetics of this regimen in these patients. IV. Determine tumor
      response in patients treated with this regimen.

      OUTLINE: This is a multicenter, dose-escalation study of
      17-N-allylamino-17-demethoxygeldanamycin (17-AAG). Patients receive 17-AAG IV over 1 hour on
      days 1*, 4, 8, 11, 15 and 18 and paclitaxel IV over 1 hour on days 1, 8, and 15. Treatment
      repeats every 28 days for 6 courses in the absence of disease progression or unacceptable
      toxicity.

      NOTE: *17-AAG is not administered on day 1 of course 1. Cohorts of 3-6 patients receive
      escalating doses of 17-AAG until the maximum tolerated dose (MTD) is determined. The MTD is
      defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience
      dose-limiting toxicity. Once the MTD is determined, 6-12 patients are treated at the
      recommended phase II dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 2 recommended doses of tanespimycin</measure>
    <time_frame>28 days</time_frame>
    <description>Tabulated according to the NCI CTC.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment (tanespimycin, paclitaxel)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 17-AAG IV over 1 hour on days 1*, 4, 8, 11, 15 and 18 and paclitaxel IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tanespimycin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (tanespimycin, paclitaxel)</arm_group_label>
    <other_name>17-AAG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (tanespimycin, paclitaxel)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>TAX</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (tanespimycin, paclitaxel)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (tanespimycin, paclitaxel)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed solid malignancy

               -  Metastatic or unresectable disease

          -  Not amenable to standard curative or palliative therapy

          -  No known brain metastases

          -  Performance status - ECOG 0-2

          -  More than 12 weeks

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  WBC ≥ 3,000/mm^3

          -  AST and ALT ≤ 2.5 times upper limit of normal

          -  Bilirubin normal

          -  Creatinine normal

          -  Creatinine clearance ≥ 60 mL/min

          -  QTc &lt; 450 msec for male patients (470 msec for female patients)

          -  LVEF &gt; 40% by MUGA

          -  No history of serious ventricular arrhythmia (i.e., ventricular tachycardia or
             ventricular fibrillation ≥ 3 beats in a row)

          -  No myocardial infarction within the past year

          -  No New York Heart Association class III or IV congestive heart failure

          -  No poorly controlled angina

          -  No history of uncontrolled dysrhythmia or requirement for antiarrhythmic drugs

          -  No history of congenital long QT syndrome

          -  No active ischemic heart disease within the past year

          -  No left bundle branch block

          -  No other significant cardiac disease

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective double barrier contraception for at least 1 week
             before, during, and for at least 2 weeks after study participation

          -  No prior allergy to eggs

          -  No prior allergic reaction to compounds of similar chemical or biologic composition to
             17-AAG or paclitaxel

          -  No peripheral neuropathy &gt; grade 1

          -  No concurrent uncontrolled illness

          -  No active or ongoing infection

          -  No psychiatric illness or social situation that would preclude study compliance

          -  No concurrent granulocyte colony-stimulating factors

          -  Prior paclitaxel allowed

          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and
             recovered

          -  No prior 17-N-allylamino-17-demethoxygeldanamycin (17-AAG)

          -  More than 4 weeks since prior radiotherapy

          -  No prior radiotherapy that included the heart in the field (e.g., mantle radiotherapy)

          -  No concurrent combination antiretroviral therapy for HIV-positive patients

          -  No concurrent therapeutic-dose warfarin for anticoagulation

          -  No concurrent medications that may prolong QTc interval

          -  No other concurrent investigational agents

          -  No other concurrent anticancer agents or therapies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suresh Ramalingam</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2004</study_first_submitted>
  <study_first_submitted_qc>July 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2004</study_first_posted>
  <last_update_submitted>January 24, 2013</last_update_submitted>
  <last_update_submitted_qc>January 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

